Compare ARBE & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBE | CRBP |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.0M | 134.8M |
| IPO Year | N/A | 2014 |
| Metric | ARBE | CRBP |
|---|---|---|
| Price | $0.79 | $8.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $2.38 | ★ $46.17 |
| AVG Volume (30 Days) | ★ 2.5M | 157.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 64.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $743.57 | N/A |
| Revenue Next Year | $326.31 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $0.76 | $4.64 |
| 52 Week High | $2.88 | $20.56 |
| Indicator | ARBE | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 32.21 | 51.67 |
| Support Level | N/A | $7.77 |
| Resistance Level | $1.46 | $8.50 |
| Average True Range (ATR) | 0.08 | 0.49 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 7.25 | 65.13 |
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.